Hospitalization/Severe Disease mRNA ■ non-mRNA ■ Multiple Study Country Design VE (95% CI) Study End Date in 2021 С Bar-On et al., 2021 0.95 (0.92, 0.97) Israel Barda et al., 2021 MC \vdash 0.93 (0.88, 0.97) Israel С Muhsen et al., 2022 0.93 (0.85, 0.97) Israel Sharma et al., 2021 USA MC 0.45 (0.27, 0.58) Mattiuzzi and Lippi, 2022 С 0.69 (0.56, 0.78) Italy С McConeghy et al., 2022 (S1) USA 0.82 (0.56, 0.94) USA С McConeghy et al., 2022 (S2) 0.46 (-0.16, 0.79)USA MC 0.81 (0.80, 0.82) Mehta et al., 2022 USA С Tartof et al., 2022 0.70 (0.48, 0.83) MC Butt et al, 2022 USA 0.52 (0.46, 0.57) UK Hulme et al., 2022 MC 0.80 (0.78, 0.82) Study End Date in 2022 Andersson et al., 2022 Finland MC 0.96 (0.88, 1.00) Andersson et al., 2022 MC 0.88 (0.71, 1.00) Norway 0.90 (0.80, 1.00) Andersson et al., 2022 Sweden MC MC 0.88 (0.81, 0.95) Andersson et al., 2022 Sweden USA \vdash loannou et al., 2022 MC 0.53 (0.48, 0.58) Ng et al., 2022 С Singapore 0.70 (0.49, 0.82) Kislaya et al., 2022 (60-79yo) Portugal С 0.21 (0.02, 0.36) С Kislaya et al., 2022 (80+yo) Portugal 0.16 (0.01, 0.28) Ridgway et al., 2022 USA **MCC** \vdash 0.59 (0.54, 0.63) Desai et al., 2022 USA MC 0.44 (0.02, 0.68) 0.80 (0.56, 0.91) Chemaitelly et al., 2022 Qatar MC -0.250.25 0 0.5 0.75 Vaccine Effectiveness (VE)

Primary Series



